| Longitudinal HIV sequencing reveals reservoir expression leading to decay which is obscured by clonal expansion MR Pinzone, DJ VanBelzen, S Weissman, MP Bertuccio, LM Cannon, ... Nature communications 10 (1), 728, 2019 | 155 | 2019 |
| Evidence that CD32a does not mark the HIV-1 latent reservoir CE Osuna, SY Lim, JL Kublin, R Apps, E Chen, TM Mota, SH Huang, ... Nature 561 (7723), E20, 2018 | 64 | 2018 |
| HIV integration and the establishment of latency in CCL19-treated resting CD4+ T cells require activation of NF-κB S Saleh, HK Lu, V Evans, D Harisson, J Zhou, A Jaworowski, G Sallmann, ... Retrovirology 13 (1), 49, 2016 | 34 | 2016 |
| Establishment of a novel humanized mouse model to investigate in vivo activation and depletion of patient-derived HIV latent reservoirs NC Flerin, A Bardhi, JH Zheng, M Korom, J Folkvord, C Kovacs, E Benko, ... Journal of virology 93 (6), e02051-18, 2019 | 29 | 2019 |
| HIV latency reversing agents act through Tat post translational modifications G Khoury, TM Mota, S Li, C Tumpach, MY Lee, J Jacobson, L Harty, ... Retrovirology 15 (1), 36, 2018 | 27 | 2018 |
| Ex vivo response to histone deacetylase (HDAC) inhibitors of the HIV long terminal repeat (LTR) derived from HIV-infected patients on antiretroviral therapy HK Lu, LR Gray, F Wightman, P Ellenberg, G Khoury, WJ Cheng, TM Mota, ... PLoS One 9 (11), e113341, 2014 | 27 | 2014 |
| HLA-C downregulation by HIV-1 adapts to host HLA genotype ND Bachtel, G Umviligihozo, S Pickering, T Mota, H Liang, GQ Del Prete, ... PLoS pathogens 14 (9), e1007257, 2018 | 26 | 2018 |
| Myeloid dendritic cells induce HIV latency in proliferating CD4+ T cells NA Kumar, RM van der Sluis, T Mota, R Pascoe, VA Evans, SR Lewin, ... The Journal of Immunology 201 (5), 1468-1477, 2018 | 19 | 2018 |
| Have Cells Harboring the HIV Reservoir Been Immunoedited? SH Huang, C McCann, T Mota, RB Jones Frontiers in Immunology 10, 1842, 2019 | 16 | 2019 |
| No adverse safety or virological changes two years following vorinostat in HIV-infected individuals on antiretroviral therapy TM Mota, TA Rasmussen, A Rhodes, S Tennakoon, A Dantanarayana, ... AIDS (London, England) 31 (8), 1137, 2017 | 13 | 2017 |
| Understanding factors that modulate the establishment of HIV latency in resting CD4+ T-cells in vitro JL Anderson, TM Mota, VA Evans, N Kumar, SD Rezaei, K Cheong, ... PloS one 11 (7), e0158778, 2016 | 11 | 2016 |
| Expression of Host Restriction Factors by Memory CD4+ T Cells Differs Between Healthy Donors and HIV-1-Infected Individuals with Effective Antiretroviral Therapy ND Bachtel, GA Beckerle, TM Mota, MM Rougvie, RAS Raposo, RB Jones, ... AIDS research and human retroviruses 35 (1), 108-111, 2019 | 6 | 2019 |
| Application of a case–control study design to investigate genotypic signatures of HIV-1 transmission TM Mota, JM Murray, RJ Center, DFJ Purcell, JM McCaw Retrovirology 9 (1), 54, 2012 | 6 | 2012 |
| Differentiating founder and chronic HIV envelope sequences JM Murray, S Maher, T Mota, K Suzuki, AD Kelleher, RJ Center, D Purcell PloS one 12 (2), e0171572, 2017 | 3 | 2017 |
